LX01-315-02 / A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with 2 mg Intralesional Allovectin-7R Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects with Recurrent Metastatic Melanoma - Allovectin-7R Immunotherapy for Metastatic Melanoma (A.I.M.M.)

Trial Profile

LX01-315-02 / A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with 2 mg Intralesional Allovectin-7R Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects with Recurrent Metastatic Melanoma - Allovectin-7R Immunotherapy for Metastatic Melanoma (A.I.M.M.)

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Aug 2014

At a glance

  • Drugs Velimogene aliplasmid (Primary) ; Dacarbazine; Temozolomide
  • Indications Malignant melanoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms AIMM
  • Sponsors Vical
  • Most Recent Events

    • 12 Sep 2013 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 12 Aug 2013 Top-line results published in a Vical media release.
    • 12 Aug 2013 The development programme for velimogene aliplasmid has been discontinued, based on the outcome of this trial, according to a Vical media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top